Abstract
The management of acute coronary syndrome (ACS) has been at the center of an impressive amount of research leading to a significant improvement in outcomes over the last 50 years. The 2020 European Society of Cardiology (ESC) Guidelines for the management of patients presenting without persistent ST-segment elevation myocardial infarction have incorporated the most recent breakthroughs and updates from large randomized controlled trials (RCT) on the diagnosis and management of this disease. The purpose of the present review is to describe the main novelties and the rationale behind these recommendations. Hence, we describe the accumulating evidence against P2Y12 receptors inhibitors pretreatment prior to coronary angiography, the preference for prasugrel as leading P2Y12 inhibitors in the setting of ACS, and the numerous available antithrombotic regimens based on various durations of dual or triple antithrombotic therapy, according to the patient ischemic and bleeding risk profiles. We also detail the recently implemented 0 h/1 h and 0 h/2 h rule in, rule out algorithms and the growing role of computed coronary tomography angiography to rule out ACS in patients at low-to-moderate risk.
Highlights
Despite tremendous achievements in its management, coronary artery disease (CAD) remains a leading cause of mortality worldwide [1,2]
To further improve outcomes following acute coronary syndrome (ACS), it is paramount for physicians dealing with such patients to implement in clinical practice the latest findings from large randomized controlled trials (RCT)
The purpose of the European Society of Cardiology (ESC) guidelines is to summarize and evaluate available evidence to facilitate decision making processes and to propose the best management of patients according to their specific situations and potential comorbidities
Summary
Despite tremendous achievements in its management, coronary artery disease (CAD) remains a leading cause of mortality worldwide [1,2]. To further improve outcomes following acute coronary syndrome (ACS), it is paramount for physicians dealing with such patients to implement in clinical practice the latest findings from large RCTs. The purpose of the ESC guidelines is to summarize and evaluate available evidence to facilitate decision making processes and to propose the best management of patients according to their specific situations and potential comorbidities. The purpose of the ESC guidelines is to summarize and evaluate available evidence to facilitate decision making processes and to propose the best management of patients according to their specific situations and potential comorbidities This year, the ESC updated their guidelines with respect to the diagnosis and management of patients presenting with non-ST-segment-elevation ACS (NSTE-ACS) [4,5]. The purpose of the present review is to summarize the main novelties of these guidelines and detailed the evidence and data that led to these updates
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
